Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 5;41(10):240.
doi: 10.1007/s12032-024-02481-8.

The role of IL-22 in cancer

Zachary E Hunzeker #  1   2   3 , Lei Zhao #  4 , Austin M Kim  1 , Jacob M Parker  1 , Ziwen Zhu  2 , Huaping Xiao  1   2 , Qian Bai  2 , Mark R Wakefield  2   5 , Yujiang Fang  6   7   8
Affiliations
Review

The role of IL-22 in cancer

Zachary E Hunzeker et al. Med Oncol. .

Abstract

Interleukin-22, discovered in the year of 2000, is a pleiotropic Th17 cytokine from the IL-10 family of cytokines. IL-22 signals through the type 2 cytokine receptor complex IL-22R and predominantly activates STAT3. This pathway leads to the transcription of several different types of genes, giving IL-22 context-specific functions ranging from inducing antimicrobial peptide expression to target cell proliferation. In recent years, it has been shown that IL-22 is involved in the pathogenesis of neoplasia in some cancers through its pro-proliferative and anti-apoptotic effects. This review highlights studies with recent discoveries and conclusions drawn on IL-22 and its involvement and function in various cancers. Such a study may be helpful to better understand the role of IL-22 in cancer so that new treatment could be developed targeting IL-22.

Keywords: Cytokine; Interleukin-22; Tumor.

PubMed Disclaimer

References

    1. Dudakov JA, Hanash AM, van den Brink MRM. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33:747–85. https://doi.org/10.1146/annurev-immunol-032414-112123 . - DOI - PubMed - PMC
    1. Shuttleworth S, Townsend P, Silva F, et al. Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases. Prog Med Chem. 2011;50:109–33. https://doi.org/10.1016/b978-0-12-381290-2.00003-3 . - DOI - PubMed
    1. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol Mucosal Immun. 2010. https://doi.org/10.1016/b978-0-12-381300-8.00001-0 . - DOI
    1. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29(1):71–109. https://doi.org/10.1146/annurev-immunol-031210-101312 . - DOI - PubMed
    1. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. J Biol Chem. 2002;277(37):33676–82. https://doi.org/10.1074/jbc.m204204200 . - DOI - PubMed

LinkOut - more resources